Founded Just a Year Ago, Telavant Sells for $7.1 Billion as Roche and Merck Vie for TL1A Antibody Leadership

Just now, Roche announced that it has reached a definitive acquisition agreement with Telavant Holdings to acquire this company and its blockbuster drug — TL1A antibody RVT-3101 for $7.1 billion.

According to the transaction announcement, in addition to the $7.1 billion acquisition price, Roche may pay an additional $150 million in near-term milestone payments. The deal is expected to be completed this quarter or next quarter. Roche stated that the company will start Phase III clinical trials of RVT-3101 as soon as possible and will own the development, production, and commercialization rights of the drug in the United States and Japan, while Pfizer will retain commercialization rights in other regions.

The core asset of this transaction, RVT-3101, is a highly anticipated new therapy primarily used for treating inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). IBD is a group of chronic gastrointestinal diseases, with nearly 80 million people diagnosed worldwide, 80% of whom have not achieved lasting remission. Given its novel mechanism of action targeting both inflammation and fibrosis, this antibody holds promise for application in a variety of other diseases.

Roche Chief Medical Officer Levi Garraway said in a statement, "The recent Phase IIb study of RVT-3101 has provided, for the first time, a long-term, reliable dataset demonstrating improved clinical remission during the maintenance treatment phase."

Beyond RVT-3101, Roche also has the potential to acquire a follow-up asset from Pfizer. Roche stated that it can initiate global cooperation with Pfizer regarding the p40/TL1A bispecific antibody currently in Phase I studies.

This deal is a huge win for Roivant, making a large profit in just one year.

Last November, Roivant acquired RVT-3101 from Pfizer and invested $45 million to establish a joint venture, Telavant, to accelerate the drug's development, with a commitment to invest more in its development. Currently, Pfizer holds 25% of Telavant's shares (valued at $87.7 million).

Now, this deal has set the stage for a showdown between Roche and Merck in the TL1A inhibitor competition. In April this year, Merck acquired Prometheus Biosciences for $10.8 billion to incorporate the latter's TL1A project, PRA023, into its product pipeline.

Analysts predict that by 2030, the market size of IBD will exceed $49 billion. This single opportunity could make PRA-023 or RVT-3101 a "blockbuster."

Therefore, Prometheus and Roivant have long been in open competition, with both companies' CEOs talking up their own drugs at investor presentations and in media interviews. As early as July or August this year, Roivant CEO Matt Gline hinted at a possible deal for the drug, but the company would wait for key data from its Immunovant division in September.

Of course, RVT-3101 faces competition not only from the TL1A antibody contender PRA-023 but also, in the broader UC space, Roivant is comparing RVT-3101 with the already approved Rinvoq, Stelara, Zeposia, and the investigational mirikizumab.

References:
1.RoivantflipsulcerativecolitisdrugtoRochefor$7.1B,lessthanayearaftergettingthedrugfromPfizer；Endpoints
2. Is the TL1A antibody, which has not yet been fully developed, worth Roche's $7 billion investment?; Insight

Editor: Bai Ji

Disclaimer: This article is a reprint from PharmNet. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues related to the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.